阿斯利康的 Fasenra 在后期试验中未能减少慢性阻塞性肺病的发作，但 Saphnelo 在狼疮试验中取得了成功。 AstraZeneca's Fasenra failed to reduce COPD flare-ups in a late-stage trial, but Saphnelo succeeded in a lupus trial.

AstraZeneca的哮喘药物Fassenra没有在对重症监护病人的后期试验中达到其主要目标,与安慰剂相比,未能减少突发事件。 AstraZeneca's asthma drug Fasenra did not meet its primary goal in a late-stage trial for COPD patients, failing to reduce flare-ups compared to a placebo. 这项研究包括过去或现在的吸烟者,过去一年中至少有两次恶化。 The study included current or former smokers with a history of at least two exacerbations in the past year. 尽管遭受挫折,该公司继续开发其他抗逆转录病毒药物治疗方法,包括Breztri空气圈和tozorakimab。 Despite the setback, the company continues developing other COPD treatments, including Breztri Aerosphere and tozorakimab. 与此同时,AstraZeneca报告说,其稀有疾病药物Saphnelo取得了成功,该药物在一次狼疮试验中达到其主要终点。 Meanwhile, AstraZeneca reported success with its rare disease drug Saphnelo, which met its primary endpoint in a lupus trial.